EU Annex 11 for US labs and device makers
Published 14 min read
Fig. 01EU GMP Annex 11 is the European Commission's guidance on computerised systems used in making medicines. Its PDF runs five pages: a principle, seventeen numbered clauses and a short glossary, in operation since 30 June 2011. A US lab, contract tester, software vendor or device maker meets it when its work or its software feeds a medicine released in the EU. This guide walks every clause in plain words, says who it binds and how it reaches a US team, and gives the status of the revision consulted on in 2025.
What Annex 11 is
Document record, as published by the European Commission
- Title
- Annex 11: Computerised Systems
- Part of
- EudraLex Vol 4, EU GMP Guide (human and veterinary medicines)
- Status
- revision 1 (index: revision January 2011)
- In operation
- 2011-06-30
- Legal basis
- Art. 47 Dir. 2001/83/EC; Art. 51 Dir. 2001/82/EC
- Contents
- Principle, 17 clauses, glossary (5 pages)
- Revision
- draft consulted 2025-07-07 to 2025-10-07, closed
- In force
- the 2011 text (EudraLex index, read 2026-10-22)
Annex 11 sits in Volume 4 of EudraLex, the EU's rules for medicinal products, beside the other annexes of the GMP Guide (sterile products, biologicals, qualification and validation, QP batch release). Its own cover page says it “provides guidance for the interpretation of the principles and guidelines of good manufacturing practice” laid down in the GMP directives, and that it was revised “in response to the increased use of computerised systems and the increased complexity of these systems”.
It is short because it states outcomes, not mechanisms. Where FDA's 21 CFR Part 11 lists specific controls, Annex 11 tells you to decide how far to go from a documented risk assessment, then to prove it across the system's whole life: requirements, suppliers, testing, operation, review and retirement.
Takeaway
Read the annex as an EU inspector or QP auditor will: every clause is a question about evidence. The “Shown by” lines below give the record that answers each one.
Who it binds, and where it reaches you
Annex 11 binds directly only those who need an EU manufacturing or import authorisation. The GMP Guide's Introduction says it is used in assessing those applications “and as a basis for inspection of manufacturers of medicinal products”. A US company is reached at one remove, through the EU firm that relies on its work. The texts show five positions:
Scroll sideways for every column
| Your position | How Annex 11 reaches you | Where it says so |
|---|---|---|
| You hold an EU manufacturing or import authorisation (an EU site) | Bound directly. The GMP Guide is the basis for inspecting authorised manufacturers, and Annex 11 is part of it. | Vol 4 Introduction |
| You make a medicine, or a step of one, that an EU importer releases | Each batch is certified by a QP in the EU. The QP must be sure every step was done under GMP; for sites in third countries, audits judge GMP “at least equivalent” to the EU’s. Your computerised systems sit inside what that audit judges. | Annex 16 § 1.1, 1.7.1, 1.7.3, 2.2(ii) |
| You test samples or process GMP data for an EU manufacturer (contract lab, CRO doing GMP work) | You are a third party. The manufacturer needs a formal agreement with you that states your responsibilities, and decides by risk whether to audit you. | Annex 11 § 3.1, 3.2; Annex 16 § 1.7.18 |
| You sell, host or support software used by EU GMP sites | You are a supplier or service provider. Your customer reviews your documentation against its requirements, assesses your quality system, and may show your audit information to inspectors. | Annex 11 § 3.3, 3.4, 4.5 |
| You make medical devices only | Not by itself. The annex rests on the EU medicinal-product directives and never names devices. It reaches you only through one of the rows above, for example as a supplier to a drug maker. | Annex 11 legal-basis line |
Middle column: our reading of the cited texts, read 2026-10-22. General information, not regulatory advice.
The US–EU mutual recognition agreement
FDA has MRAs in force with the EU, which let drug inspectors “rely upon information from drug inspections conducted within each other's borders”. Annex 16 names one effect: without an MRA or similar agreement, the QP must make sure an imported batch was fully re-tested in a Member State (§ 1.5.4). The MRA is about who inspects. It does not remove the QP's duty to be sure every step was done under GMP, or your EU customer's need for a supplier agreement with you.
Two edges of scope. Annex 11 is a GMP text: a CRO whose work is clinical answers to the EU's clinical trial rules, which this guide does not cover, while a CRO or contract lab doing GMP testing for an EU batch is a third party under § 3. And for veterinary medicines the EudraLex index now lists separate GMP regulations (Implementing Regulation (EU) 2025/2091, in application since 16 July 2026); this guide reads the human-medicine side.
Takeaway
Find your row. If you are a supplier or contract lab, ask your EU customer for its quality agreement and its supplier questionnaire early; they will be built on § 3. Qualifying suppliers is the job compared in supplier quality management software.
The principle and §§ 1–3
The annex groups its clauses in three parts: General, Project Phase and Operational Phase. The general part sets the frame every later clause depends on: what is in scope, risk as the measure, people, and suppliers.
Principle
Scope and the two basic duties
The annex covers “all forms of computerised systems used as part of a GMP regulated activities”, and a computerised system is software and hardware that together do a job. Two duties follow: “The application should be validated; IT infrastructure should be qualified.” A system that replaces a manual step must not lower product quality, process control or quality assurance, and must not raise the overall risk of the process.
Shown by: A validation report for the application, qualification records for the servers, network or hosting under it, and, where a paper step was replaced, the risk comparison.
§ 1
Risk management
Risk management runs through the whole life of the system, weighing patient safety, data integrity and product quality. How far you validate and which data integrity controls you build are “based on a justified and documented risk assessment”.
Shown by: One written risk assessment per system that explains why validation went as deep as it did, and no deeper.
§ 2
Personnel
Process owner, system owner, Qualified Persons and IT work closely together. Everyone has the right qualifications, the right level of access and written responsibilities. The glossary defines the two owners: the process owner is responsible for the business process, the system owner for the system's availability, maintenance and the security of its data.
Shown by: A named process owner and system owner for each system, role descriptions, and training records that match the access each person holds.
§ 3
Suppliers and service providers
When a third party provides, installs, configures, integrates, validates, maintains (remote access included), modifies or retains a system, or processes data, “formal agreements must exist” that state the third party's responsibilities (3.1). An in-house IT department counts the same way. Whether to audit a supplier is “based on a risk assessment” (3.2). The regulated user reviews the documentation that comes with off-the-shelf software against its own user requirements (3.3), and supplier quality and audit information is “made available to inspectors on request” (3.4).
This is the clause that reaches most US vendors and contract labs. How to qualify a cloud vendor is set out in Part 11 for cloud and SaaS systems.
Shown by: A signed quality agreement with every supplier that touches the system or its data, a supplier assessment, and either an audit report or the risk reasoning for not auditing.
Project phase: § 4 validation
Clause 4 is the longest in the annex, eight paragraphs on getting a system validated before it holds GMP data. It fits the lifecycle in our computer system validation guide for small labs.
§ 4.1–4.2
Validation scope and records
Validation documents and reports cover the relevant steps of the life cycle, and the manufacturer can justify its standards, protocols, acceptance criteria and records from its risk assessment. The validation pack includes change control records where they apply and reports on every deviation found during validation.
Shown by: A validation plan and report that name the life-cycle steps covered, with each test deviation written up and closed.
§ 4.3
Inventory and system description
An up-to-date list of all relevant systems and their GMP functions. For critical systems, a current description of the physical and logical set-up, data flows, interfaces, hardware and software prerequisites, and security measures.
Shown by: A system inventory with a GMP-impact column, and a system description (a data-flow diagram helps) for each critical system.
§ 4.4
User requirements
The user requirements specification describes what the system must do, is based on documented risk and GMP impact, and stays “traceable throughout the life-cycle”.
Shown by: A numbered URS (the URS template builds one) traced to tests in a matrix.
§ 4.5–4.6
Supplier quality and bespoke systems
The regulated user takes all reasonable steps to make sure the system was developed under an appropriate quality management system, and the supplier is “assessed appropriately”. For bespoke or customised systems there is a process for formally assessing and reporting quality and performance measures at every life-cycle stage.
Shown by: Evidence that the developer works under a quality system (an audit, a questionnaire, certificates), and for custom code, the development and test records.
§ 4.7
Testing
Test methods and scenarios are shown to be appropriate. Parameter limits, data limits and error handling get particular attention. Automated test tools and test environments have documented assessments of their adequacy.
Shown by: Test scripts that push limits and bad inputs, not only the happy path, and a short assessment of any automated test tool used.
§ 4.8
Data migration
When data moves to another format or system, validation checks that it is “not altered in value and/or meaning” on the way.
Shown by: A migration protocol with record counts and a sample of values compared before and after, signed off.
Takeaway
The § 4.3 inventory is the cheapest place to start and the first thing many auditors ask for. List every system, mark its GMP impact, and the rest of the validation plan follows from that list.
Operational phase: §§ 5–17
Thirteen clauses on running a validated system: how data goes in, is kept, printed, changed, secured, signed, released, recovered and archived. Most of them leave a record you can show.
§ 5
Data
Systems that exchange data electronically with other systems have built-in checks that the data goes in and is processed correctly and securely.
Shown by: Interface tests in the validation pack: a record sent, a record received, a malformed record rejected.
§ 6
Accuracy checks
Critical data typed in by hand gets a second check, by another operator or by a validated electronic means. How critical the data is, and what a wrong entry would cause, is covered by risk management.
Shown by: A list of the hand-entered critical fields and the second check on each (a witness signature or a validated range check).
§ 7
Data storage
Data is protected against damage by physical and electronic means, checked for accessibility, readability and accuracy, and “Access to data should be ensured throughout the retention period” (7.1). Relevant data is backed up regularly, and the integrity of the back-up and the ability to restore it are checked during validation and monitored periodically (7.2).
Shown by: A back-up schedule and a dated restore test, repeated on a set interval, not just once at go-live.
§ 8
Printouts
You can get clear printed copies of stored data (8.1). For records supporting batch release, a printout can show whether any data was changed since the original entry (8.2).
Shown by: A printout of a batch-release record that flags changed values, produced live in front of the auditor.
§ 9
Audit trails
“Consideration should be given, based on a risk assessment” to building in a system-generated record of all GMP-relevant changes and deletions. The reason for a change or deletion of GMP-relevant data is documented. Audit trails are available, convertible to “a generally intelligible form”, and “regularly reviewed”.
Note the review duty: Part 11 asks for the trail but sets no review. What a trail must capture is covered in what an audit trail is in GxP.
Shown by: A reason-for-change field switched on, and dated records of trail review (the audit trail review checklist sets one up).
§ 10
Change and configuration management
Any change to a system, configuration included, is made only in a controlled way under a defined procedure.
Shown by: A change control SOP and the change records for the last configuration changes, each with its impact assessment.
§ 11
Periodic evaluation
Systems are “periodically evaluated to confirm that they remain in a valid state and are compliant with GMP”. Where it fits, the evaluation looks at functions in use, deviations, incidents, problems, upgrade history, performance, reliability, security and validation status.
Shown by: A dated periodic review report per system that walks those topics and ends with a conclusion: still valid, or what must be revalidated.
§ 12
Security
Physical or logical controls limit access to authorised people; keys, pass cards, personal codes with passwords and biometrics are all named as options (12.1). How strict depends on how critical the system is (12.2). Creating, changing and cancelling access rights is recorded (12.3). Systems record who entered, changed, confirmed or deleted data, with the date and time (12.4).
Shown by: An access request and removal log, a current user list reconciled against staff, and one login per person.
§ 13
Incident management
All incidents, not only system failures and data errors, are reported and assessed. The root cause of a critical incident is found and becomes the basis for corrective and preventive action.
Shown by: An incident log for the system, with critical incidents linked to a CAPA record.
§ 14
Electronic signature
Records may be signed electronically. An electronic signature is expected to carry the same weight as a handwritten one inside the company, be “permanently linked to their respective record”, and include the time and date it was applied. It names no printed name or meaning on the signed record; Part 11's § 11.50 does, and the signature manifestation check tests that.
Shown by: A signed record showing the date and time, a test that the signature cannot be copied to another record, and a policy that e-signatures bind like handwritten ones.
§ 15
Batch release
Where a system records certification and batch release, only Qualified Persons can certify, the system identifies and records the person releasing, and “This should be performed using an electronic signature.”
Shown by: Role configuration that lets only QPs release, and a release record carrying the QP's e-signature.
§ 16
Business continuity
For systems that support critical processes, there are arrangements to keep the process going if the system breaks down, such as a manual or alternative system. The time to switch over is based on risk, and the arrangements are documented and tested.
Shown by: A written fallback for each critical system and a record that it was tested, with the switch-over time.
§ 17
Archiving
Archived data is checked for accessibility, readability and integrity. Before relevant changes to the system (new equipment or software), the ability to retrieve the archive is ensured and tested.
Shown by: An archive retrieval test run after each upgrade or migration, with the records it pulled back.
Inspection risk
Clauses 11, 13 and 16 have no Part 11 counterpart, so a pack built only for Part 11 will not have them: a periodic evaluation report, an incident log for the system, a tested business continuity plan. Each is a record that cannot be back-dated once the auditor asks.
Where it reads differently from Part 11
A US team that already runs to Part 11 has most of the record and signature ground covered. The two texts are built differently, though, and the difference shows up in audits. Part 11 is a regulation: persons who use closed systems “shall employ procedures and controls”, and § 11.10 lists them. Annex 11 is guidance written in “should”, and it hangs almost every control on a documented risk assessment.
- Annex 11 reaches further along the life cycle. Risk management (§ 1), supplier agreements (§ 3), periodic evaluation (§ 11), incident management (§ 13), QP batch release (§ 15) and business continuity (§ 16) have no Part 11 counterpart in our mapping.
- Part 11 is more exact about signatures. It asks for the printed name and the meaning on the signed record (§ 11.50), two distinct components to sign (§ 11.200(a)), password and token controls (§ 11.300) and a certification letter to FDA (§ 11.100(c)). Annex 11 § 14 asks for none of these by name.
- Audit trails cut both ways. Part 11 requires the trail for records in its scope (§ 11.10(e)) but sets no review. Annex 11 leaves the trail to risk, then asks for a reason on every GMP-relevant change and for regular review.
Every section of Part 11 laid beside its Annex 11 clause, with the gaps you can export, is in the Annex 11 vs Part 11 mapping tool. Part 11's side, section by section, is in 21 CFR Part 11 requirements.
Takeaway
Build one control set that satisfies both. In practice that means writing the Annex 11 extras (risk assessment, supplier agreements, periodic review, incident log, continuity test) into the same validation pack that already carries your Part 11 evidence.
The 2025 revision: where it stands
On 7 July 2025 the European Commission opened a stakeholder consultation on three draft texts: a revised Chapter 4 (Documentation), a revised Annex 11 and a new Annex 22 on artificial intelligence. The deadline was 7 October 2025, and the consultation page now reads “Closed”. The page says the three documents “have been drafted by the EMA GMDP-Inspectors Working Group in cooperation with the PIC/S”.
How the consultation page itself describes each draft:
- Annex 11: “enhanced requirements for the lifecycle management of computerised systems”, with Quality Risk Management applied at every step, stronger obligations on system requirements and on overseeing suppliers and service providers, and stronger controls on data integrity, audit trails, electronic signatures and system security.
- Chapter 4: risk management built into the data governance system across paper, digital and hybrid records, and clarified requirements for electronic records, signatures and data integrity, consistent with the Annex 11 revision.
- Annex 22: requirements for AI and machine learning in manufacturing active substances and medicinal products, covering the selection, training and validation of models.
That is all the Commission has published about the outcome. As read on 2026-10-22, the EudraLex Volume 4 index still lists “Annex 11 Computerised Systems (revision January 2011)” and “Chapter 4 - Documentation (January 2011)”, and no Annex 22. The 2011 text is the one in force.
Common misreading
“The new Annex 11 is in force” or “Annex 11 was revised in 2025”. Neither is true as of 2026-10-22. The 2025 texts were drafts for comment. Read them to see the direction of travel; audit and validate against the 2011 annex.
Takeaway
Check the EudraLex Volume 4 index before each periodic review. If a final text appears there, read its “deadline for coming into operation” line; the 2011 annex carried one (30 June 2011).
The pack an EU auditor asks for
- Inventory
- Every GMP system and what it does; a system description for the critical ones (§ 4.3).
- Risk
- A documented risk assessment per system that sets the depth of validation (§ 1).
- Suppliers
- Quality agreements, supplier assessments, audit reports or the reason for none (§ 3, § 4.5).
- Validation
- URS traced to tests, test deviations closed, migration checks where data moved (§ 4).
- Data
- Back-up schedule and dated restore tests; second checks on hand-entered critical data (§ 6, § 7).
- Audit trail
- Reason for change switched on; records that the trail is reviewed (§ 9).
- Access
- Logged grants and removals; one login per person; operator, date and time on every entry (§ 12).
- Change and incidents
- Change control records; an incident log tied to CAPA (§ 10, § 13).
- Periodic review
- A dated report per system confirming it is still in a valid state (§ 11).
- Continuity
- A tested fallback for critical systems; archive retrieval tested after changes (§ 16, § 17).
Built from the clauses above; our reading, not a list the annex prints. The records-integrity side of the same pack is in the ALCOA+ principles guide.
Questions
Is Annex 11 law?
It is guidance. The annex says it “provides guidance for the interpretation of the principles and guidelines of good manufacturing practice” set in the EU GMP directives, and it is written in “should”. In practice the GMP Guide is used “as a basis for inspection of manufacturers” (its own Introduction), so inspectors and the QPs who audit you read your systems against it.
Does Annex 11 apply to medical device makers?
Not for a device on its own. The annex sits in the GMP guide for medicinal products and its legal basis is the human and veterinary medicines directives. A device maker meets it when part of its work feeds an EU medicine: as a supplier or service provider to a drug maker, or where it manufactures for a medicinal product.
If our system is Part 11 compliant, is it Annex 11 compliant?
Partly. Much of the record and signature ground overlaps, but Annex 11 adds clauses Part 11 does not have, such as risk management, supplier agreements, periodic evaluation, incident management and business continuity. The Annex 11 vs Part 11 mapping lists the gaps clause by clause.
Does Annex 11 require an audit trail on every system?
No. § 9 says “Consideration should be given, based on a risk assessment” to building one in. Where a trail exists, the reason for GMP-relevant changes and deletions is documented and the trail is regularly reviewed.
Is the revised Annex 11 in force?
No. The 2025 texts were drafts put out for consultation from 7 July to 7 October 2025. As read on 2026-10-22, the EudraLex Volume 4 index still lists Annex 11 as the January 2011 revision, and that is the text inspectors apply.
Does the US–EU mutual recognition agreement mean we can ignore Annex 11?
No. FDA's MRA with the EU lets drug inspectors rely on each other's inspections. Annex 16 names one effect: without an MRA or similar agreement, an imported batch has to be fully re-tested in a Member State (§ 1.5.4). The QP still has to be sure each step was done under GMP, and your EU customer still needs its supplier agreements.
Sources
Annex 11, Annex 16 and the consultation page quoted from the European Commission; MRA from FDA; Part 11 from the eCFR. General information, not regulatory advice.
- EudraLex Volume 4, Annex 11: Computerised Systems (revision 1, in operation 30 June 2011), European Commissionread 2026-10-22
- EudraLex Volume 4, Good Manufacturing Practice guidelines (index), European Commissionread 2026-10-22
- EU Guidelines to GMP, Introduction (2011), European Commissionread 2026-10-22
- Stakeholders' consultation on EudraLex Volume 4: Chapter 4, Annex 11 and new Annex 22, European Commissionread 2026-10-22
- EudraLex Volume 4, Annex 16: Certification by a Qualified Person and Batch Release (2015), European Commissionread 2026-10-22
- Mutual Recognition Agreements (MRA), FDAread 2026-10-22
- 21 CFR Part 11, Electronic Records; Electronic Signatures (eCFR, up to date as of 2026-10-20), eCFRread 2026-10-22